Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC
Bullboard Posts
User Avatar Image
(0)
•••
Post by toothpickon Oct 30, 2010 4:26pm
304 Views
Post# 17635652

Example of "First-in-class"

Example of "First-in-class"

Pfizer Says First-in-Class ALK Inhibitor Rapidly Advanced To Phase 3 Development

10/27/2010 7:22 PM ET

"

(RTTNews) - Pfizer Inc. (PFE: News ) announced the publication of data showing that 57% of ALK-positive advanced non-small cell lung cancer patients treated with crizotinib, an investigational oral anaplastic lymphoma kinase inhibitor, had either a complete or partial response to treatment. "
(....)

To be compared with MCC 8mg dosage = 45% complete response

wonder % of complete response in Pfizer case

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities